medigraphic.com
ISSN 1027-2852 (Digital)
ISSN 0864-4551 (Impreso)

2012, Número 1

<< Anterior Siguiente >>

Biotecnol Apl 2012; 29 (1)


Proteínas predichas de Neisseria meningitidis como posibles candidatos vacunales: de los análisis in silico a la corroboración experimental

García D, Yero D, Niebla O, Cobas K, Perera Y, Caballero E, Delgado M, Pajón R

Idioma: Ingles.
Referencias bibliográficas: 50
Paginas: 22-28
Archivo PDF: 633.24 Kb.


RESUMEN

Las infecciones producidas por el serogrupo B de Neisseria meningitidis constituyen un serio problema de salud mundial que no puede ser prevenido mediante la vacunación. En este artículo reportamos un análisis del genoma de la cepa MC58 de N. meningitidis desarrollado con el objetivo de identificar nuevos posibles candidatos vacunales. Los genes anotados como ‘Hipotéticos’ e ‘Hipotéticos conservados’, en conjunto con aquellos que pudieran presentar funciones relacionadas con la envoltura celular, estuvieron sujetos a extensos análisis de similitud de secuencia, localización celular y de motivos y dominios complementados con curación manual. Como resultado, 35 marcos de lectura abiertos no caracterizados, predichos para codificar proteínas de superficie o relacionadas con la virulencia fueron identificados. Los candidatos fueron subdivididos en tres categorías: 1) proteínas de membrana externa (PME) únicas del género Neisseria; 2) PMEs conservadas en varios géneros y 3) proteínas homólogas a PME conocidas o a proteínas previamente reportadas como inmunogénicas en modelos animales. Dos de estos candidatos, el nmb1126 y el nmb0181 fueron clonados y expresados en Escherichia coli. Los productos resultantes fueron purificados por cromatografía de afinidad a quelatos metálicos y empleados para inmunizar ratones. Las proteínas recombinantes fueron capaces de inducir anticuerpos que reconocieron el antígeno nativo del meningococo en un panel de tres cepas y que mostraron actividad bactericida contra la cepa homóloga.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Stephens DS, Zimmer SM. Pathogenesis, Therapy, and Prevention of Meningococcal Sepsis. Curr Infect Dis Rep. 2002;4(5):377-86.

  2. Tikhomirov E, Santamaria M, Esteves K. Meningococcal disease: public health burden and control. World Health Stat Q. 1997;50(3-4):170-7.

  3. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2(8346):355-7.

  4. Fredriksen JH, Rosenqvist E, Wedege E, Bryn K, Bjune G, Froholm LO, et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 1991;14(2):67-80.

  5. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14(2):195-10.

  6. Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Hoiby EA, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis. 1998;177(3):683-91.

  7. Wheeler JX, Vipond C, Feavers IM. Exploring the proteome of meningococcal outer membrane vesicle vaccines. Proteomics Clin Appl. 2007;1(9):1198-210.

  8. Masignani V, Rappuoli R, Pizza M. Reverse vaccinology: a genome-based approach for vaccine development. Expert Opin Biol Ther. 2002;2(8):895-905.

  9. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287(5459):1816-20.

  10. Snape MD, Dawson T, Morant A, John B, Ohene-Kena R, Borrow R, et al. Program and abstract of the 16th International Pathogenic Neisseria Conference (Rotterdam, Amsterdam). 7-12 September. 2008. Immunogenicity and reactogenicity of a novel serogroup B Neisseria meningitidis vaccine administered from 6 months of age. Abstract O69.

  11. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA. 2006;103(29):10834-9.

  12. Capecchi B, Adu-Bobie J, Di Marcello F, Ciucchi L, Masignani V, Taddei A, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol. 2005;55(3):687-98.

  13. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197(6):789-99.

  14. Ruckdeschel EA, Kirkham C, Lesse AJ, Hu Z, Murphy TF. Mining the Moraxella catarrhalis genome: identification of potential vaccine antigens expressed during human infection. Infect Immun. 2008;76(4):1599-607.

  15. Huntley JF, Conley PG, Hagman KE, Norgard MV. Characterization of Francisella tularensis outer membrane proteins. J Bacteriol. 2007;189(2):561-74.

  16. Lewenza S, Gardy JL, Brinkman FS, Hancock RE. Genome-wide identification of Pseudomonas aeruginosa exported proteins using a consensus computational strategy combined with a laboratory-based PhoA fusion screen. Genome Res. 2005;15(2):321-9.

  17. Zhao Y, Benita Y, Lok M, Kuipers B, van der Ley P, Jiskoot W, et al. Multi-antigen immunization using IgG binding domain ZZ as carrier. Vaccine. 2005;23(43):5082-90.

  18. Pajon R, Yero D, Niebla O, Climent Y, Sardinas G, Garcia D, et al. Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes. Vaccine. 2009;28(2):532-41.

  19. Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, et al. Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24(24):5093-107.

  20. Yero D, Pajon R, Niebla O, Sardinas G, Vivar I, Perera Y, et al. Bicistronic expression plasmid for the rapid production of recombinant fused proteins in Escherichia coli. Biotechnol Appl Biochem. 2006;44(Pt 1):27-34.

  21. Pajon R, Yero D, Niebla O, Climent Y, Sardinas G, Garcia D, et al. Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes. Vaccine. 2009;28(2):532-41.

  22. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25(17):3389-402.

  23. Marchler-Bauer A, Panchenko AR, Shoemaker BA, Thiessen PA, Geer LY, Bryant SH. CDD: a database of conserved domain alignments with links to domain three-dimensional structure. Nucleic Acids Res. 2002;30(1):281-3.

  24. Marchler-Bauer A, Anderson JB, Derbyshire MK, DeWeese-Scott C, Gonzales NR, Gwadz M, et al. CDD: a conserved domain database for interactive domain family analysis. Nucleic Acids Res 2007;35(Database issue):D237-40.

  25. Uchiyama I. MBGD: a platform for microbial comparative genomics based on the automated construction of orthologous groups. Nucleic Acids Res. 2007;35(Database issue):D343-6.

  26. Nielsen H, Krogh A. Prediction of signal peptides and signal anchors by a hidden Markov model. Proc Int Conf Intell Syst Mol Biol. 1998;6:122-30.

  27. Juncker AS, Willenbrock H, Von Heijne G, Brunak S, Nielsen H, Krogh A. Prediction of lipoprotein signal peptides in Gram-negative bacteria. Protein Sci. 2003;12(8):1652-62.

  28. Nakai K, Horton P. PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci. 1999;24(1):34-6.

  29. Wedege E, Froholm LO. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun. 1986;51(2):571-8.

  30. Delgado M, Yero D, Niebla O, Gonzalez S, Climent Y, Perez Y, et al. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate. Vaccine. 2007;25(50):8420-31.

  31. Luo Y, Glisson JR, Jackwood MW, Hancock RE, Bains M, Cheng IH, et al. Cloning and characterization of the major outer membrane protein gene (ompH) of Pasteurella multocida X-73. J Bacteriol. 1997;179(24):7856-64.

  32. Koski P, Hirvas L, Vaara M. Complete sequence of the ompH gene encoding the 16-kDa cationic outer membrane protein of Salmonella typhimurium. Gene. 1990;88(1):117-20.

  33. Ataei S, Burchmore R, Christopher Hodgson J, Finucane A, Parton R, Coote JG. Identification of immunogenic proteins associated with protection against haemorrhagic septicaemia after vaccination of calves with a live-attenuated aroA derivative of Pasteurella multocida B:2. Res Vet Sci. 2009;87(2):207-10.

  34. Tidhar A, Flashner Y, Cohen S, Levi Y, Zauberman A, Gur D, et al. The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the development of plague. PLoS One. 2009;4(9):e7023.

  35. Prieto AI, Hernandez SB, Cota I, Pucciarelli MG, Orlov Y, Ramos-Morales F, et al. Roles of the outer membrane protein AsmA of Salmonella enterica in the control of marRAB expression and invasion of epithelial cells. J Bacteriol. 2009;191(11):3615-22.

  36. Adu-Bobie J, Capecchi B, Serruto D, Rappuoli R, Pizza M. Two years into reverse vaccinology. Vaccine. 2003;21(7-8):605-10.

  37. Jacobsson S, Thulin S, Molling P, Unemo M, Comanducci M, Rappuoli R, et al. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine. 2006;24(12):2161-8.

  38. Murphy TF, Kirkham C, Lesse AJ. Construction of a mutant and characterization of the role of the vaccine antigen P6 in outer membrane integrity of nontypeable Haemophilus influenzae. Infect Immun. 2006;74(9):5169-76.

  39. Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med. 1998;339(4):216-22.

  40. Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, Schoen RT, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med. 1998;339(4):209-15.

  41. Booth PJ. The trials and tribulations of membrane protein folding in vitro. Biochim Biophys Acta. 2003;1610(1):51-6.

  42. Fong C, Rohmer L, Radey M, Wasnick M, Brittnacher MJ. PSAT: a web tool to compare genomic neighborhoods of multiple prokaryotic genomes. BMC Bioinformatics. 2008;9:170.

  43. Ferrari G, Garaguso I, Adu-Bobie J, Doro F, Taddei AR, Biolchi A, et al. Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics. 2006;6(6):1856-66.

  44. Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics. 2006;6(11):3400-13.

  45. Vaughan TE, Skipp PJ, O'Connor CD, Hudson MJ, Vipond R, Elmore MJ, et al. Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens. Vaccine. 2006;24(25):5277-93.

  46. Tsolakos N, Lie K, Bolstad K, Maslen S, Kristiansen PA, Hoiby EA, et al. Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media. Vaccine. 2010;28(18):3211-8.

  47. Moxon R, Rappuoli R. Bacterial pathogen genomics and vaccines. Br Med Bull. 2002;62:45-58.

  48. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307-26.

  49. Vasfi Marandi M, Harel J, Mittal KR. Identification by monoclonal antibodies of serotype D strains of Pasteurella multocida representing various geographic origins and host species. J Med Microbiol. 1997;46(7):603-10.

  50. Vemulapalli R, Duncan AJ, Boyle SM, Sriranganathan N, Toth TE, Schurig GG. Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B. abortus RB51. Infect Immun. 1998;66(12):5684-91.




2020     |     www.medigraphic.com